Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 220

PubMed (MeSH Keyword) for PubChem Compound (Select 25126798)

1.

[Polycythemia vera: the disadvantages of overproduction].

Aumiller J.

MMW Fortschr Med. 2015 Apr 30;157(8):18-20. doi: 10.1007/s15006-015-3012-7. German. No abstract available.

PMID:
26012664
2.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, Guglielmelli P, Fjerza R, Paoli C, Verstovsek S, Vannucchi AM.

Blood. 2015 May 21;125(21):3352-3. doi: 10.1182/blood-2015-01-624536. No abstract available.

PMID:
25999444
3.

Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.

Szymańska J, Smolewski P, Majchrzak A, Cebula-Obrzut B, Chojnowski K, Treliński J.

Adv Clin Exp Med. 2015 Mar-Apr;24(2):195-202. doi: 10.17219/acem/32934.

4.

JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter.

Wagner AH, Conzelmann M, Fitzer F, Giese T, Gülow K, Falk CS, Krämer OH, Dietrich S, Hecker M, Luft T.

Biochem Pharmacol. 2015 Jul 1;96(1):52-64. doi: 10.1016/j.bcp.2015.04.019. Epub 2015 Apr 28.

PMID:
25931145
5.

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

Schönberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, Manser AR, Uhrberg M, Verbeek W, Koschmieder S, Brümmendorf TH, Brossart P, Heine A, Wolf D.

Cancer Res. 2015 Jun 1;75(11):2187-99. doi: 10.1158/0008-5472.CAN-14-3198. Epub 2015 Apr 1.

PMID:
25832652
6.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D.

Br J Haematol. 2015 Jun;169(6):824-33. doi: 10.1111/bjh.13373. Epub 2015 Mar 30.

PMID:
25824483
7.

Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor.

Martinez-Lopez J, Jimenez A, Sanchez-Calero J, Monteagudo D, Urbanowicz M, Cañamares-Orbis I, Cortijo-Cascajares S, Ayala R.

Ann Hematol. 2015 Jul;94(7):1237-9. doi: 10.1007/s00277-015-2352-9. Epub 2015 Mar 21. No abstract available.

PMID:
25791242
8.

Sweet syndrome as terminal event in ruxolitinib-treated myelofibrosis.

Chatterjee B, Rqieh U, Greaves P, Piras D, Firth J, Saja K.

Br J Haematol. 2015 May;169(3):307. doi: 10.1111/bjh.13334. Epub 2015 Feb 23. No abstract available.

PMID:
25707420
9.

Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib.

Shi JG, Fraczkiewicz G, Williams WV, Yeleswaram S.

Clin Pharmacol Ther. 2015 Feb;97(2):177-85. doi: 10.1002/cpt.30. Epub 2014 Dec 15.

PMID:
25670523
10.

Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.

Higgins E, Al Shehri T, McAleer MA, Conlon N, Feighery C, Lilic D, Irvine AD.

J Allergy Clin Immunol. 2015 Feb;135(2):551-3. doi: 10.1016/j.jaci.2014.12.1867. No abstract available.

PMID:
25662309
11.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.

Blood. 2015 Mar 12;125(11):1759-67. doi: 10.1182/blood-2014-06-580480. Epub 2015 Feb 2.

PMID:
25645356
12.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S.

N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.

13.

Going for broke: targeting the human cancer pseudokinome.

Bailey FP, Byrne DP, McSkimming D, Kannan N, Eyers PA.

Biochem J. 2015 Jan 15;465(2):195-211. doi: 10.1042/BJ20141060. Review. Erratum in: Biochem J. 2015 Feb 15;466(1):201.

PMID:
25559089
14.

Remission of recalcitrant dermatomyositis treated with ruxolitinib.

Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J.

N Engl J Med. 2014 Dec 25;371(26):2537-8. doi: 10.1056/NEJMc1412997. No abstract available.

15.

Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.

Fournier JB, Cummings F, Cannella J, Breen C, Zhou L, Iwamoto S.

Dermatol Online J. 2014 Oct 15;20(10). pii: 13030/qt2jg3q02x.

PMID:
25526003
16.

The identification and characterization of a STAT5 gene signature in hematologic malignancies.

Sonkin D, Palmer M, Rong X, Horrigan K, Regnier CH, Fanton C, Holash J, Pinzon-Ortiz M, Squires M, Sirulnik A, Radimerski T, Schlegel R, Morrissey M, Cao ZA.

Cancer Biomark. 2015;15(1):79-87. doi: 10.3233/CBM-140434.

PMID:
25524945
17.

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.

Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, Dogan A, Intlekofer A, Manshouri T, Park CY, Verstovsek S, Rapaport F, Stephens PJ, Miller VA, Levine RL.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5401-10. doi: 10.1073/pnas.1407792111. Epub 2014 Dec 2.

18.

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ.

Blood. 2015 Feb 26;125(9):1444-51. doi: 10.1182/blood-2014-09-601062. Epub 2014 Dec 12.

19.

Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.

Ammatuna E, Eefting M, van Lom K, Kavelaars FG, Valk PJ, Touw IP.

Ann Hematol. 2015 May;94(5):879-80. doi: 10.1007/s00277-014-2272-0. Epub 2014 Dec 11. No abstract available. Erratum in: Ann Hematol. 2015 Jun;94(6):1079. Kavelaars, François F [corrected to Kavelaars, François G].

PMID:
25491280
20.

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Geyer HL, Mesa RA.

Blood. 2014 Dec 4;124(24):3529-37. doi: 10.1182/blood-2014-05-577635. Review.

PMID:
25472969
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk